PL2943215T3 - Lactoferricin derived peptides for use in the treatment of cancer - Google Patents

Lactoferricin derived peptides for use in the treatment of cancer

Info

Publication number
PL2943215T3
PL2943215T3 PL14700349T PL14700349T PL2943215T3 PL 2943215 T3 PL2943215 T3 PL 2943215T3 PL 14700349 T PL14700349 T PL 14700349T PL 14700349 T PL14700349 T PL 14700349T PL 2943215 T3 PL2943215 T3 PL 2943215T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
derived peptides
lactoferricin
lactoferricin derived
Prior art date
Application number
PL14700349T
Other languages
Polish (pl)
Inventor
Dagmar Zweytick
Karl Lohner
Sabrina Riedl
Original Assignee
Newfield Therapeutics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newfield Therapeutics Corporation filed Critical Newfield Therapeutics Corporation
Publication of PL2943215T3 publication Critical patent/PL2943215T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14700349T 2013-01-11 2014-01-09 Lactoferricin derived peptides for use in the treatment of cancer PL2943215T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13150974.7A EP2754450A1 (en) 2013-01-11 2013-01-11 Lactoferricin derived peptides
EP14700349.5A EP2943215B1 (en) 2013-01-11 2014-01-09 Lactoferricin derived peptides for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
PL2943215T3 true PL2943215T3 (en) 2017-07-31

Family

ID=47504770

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14700349T PL2943215T3 (en) 2013-01-11 2014-01-09 Lactoferricin derived peptides for use in the treatment of cancer

Country Status (7)

Country Link
US (2) US9492497B2 (en)
EP (2) EP2754450A1 (en)
DK (1) DK2943215T3 (en)
ES (1) ES2617500T3 (en)
HU (1) HUE031361T2 (en)
PL (1) PL2943215T3 (en)
WO (1) WO2014108475A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453701B2 (en) * 2017-08-18 2022-09-27 Adrx, Inc. Tau aggregation peptide inhibitors
JP7267998B2 (en) * 2017-08-19 2023-05-02 オハイオ・ステイト・イノベーション・ファウンデーション Novel peptide-based cancer contrast agent
WO2022164864A1 (en) * 2021-01-27 2022-08-04 The Regents Of The University Of Colorado, A Body Corporate Novel peptide carrier compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593866A (en) 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
GB9818938D0 (en) 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
WO2008002165A2 (en) 2006-06-30 2008-01-03 Krzysztof Kucharczyk A method, assay and kit for prediction and treatment of a human subject infected with a virus
AU2007272272B2 (en) * 2006-07-10 2012-04-12 Pba3 Biomed Gmbh Antimicrobial peptides
NZ552316A (en) 2006-12-22 2009-10-30 Fonterra Co Operative Group Dairy product and process

Also Published As

Publication number Publication date
US20160045562A1 (en) 2016-02-18
US9872891B2 (en) 2018-01-23
HUE031361T2 (en) 2017-07-28
EP2754450A1 (en) 2014-07-16
US20170042975A1 (en) 2017-02-16
US9492497B2 (en) 2016-11-15
EP2943215B1 (en) 2016-11-23
EP2943215A1 (en) 2015-11-18
WO2014108475A1 (en) 2014-07-17
ES2617500T3 (en) 2017-06-19
DK2943215T3 (en) 2017-03-06

Similar Documents

Publication Publication Date Title
IL245297B (en) Variants of fgf19 polypeptides for the treatment of cancer
IL245744A0 (en) Therapeutic peptides
HK1219983A1 (en) Therapeutic peptides
HK1222552A1 (en) Sobetirome in the treatment of myelination diseases
HK1214829A1 (en) Therapeutic peptides
HUE057061T2 (en) Combination therapy for the treatment of cancer
SI2983866T1 (en) Grinding body
GB2516335B (en) The use of phytocannabinoids in the treatment of ovarian carcinoma
IL276423B2 (en) Compositions comprising coenzyme q10 for use in the treatment of cancer
PT3089749T (en) Combined preparations for the treatment of cancer
HK1222548A1 (en) Pharmaceutical combinations for the treatment of cancer
EP3733184C0 (en) Pyrimidine compounds for use in the treatment of cancer
LT3044229T (en) Peptides for use in the treatment of oral mucositis
HK1223547A1 (en) Methods for the treatment of cancer
PL2774694T3 (en) Surface treatment system
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
LT2872176T (en) Carboranylporphyrins for use in the treatment of cancer
PL2943215T3 (en) Lactoferricin derived peptides for use in the treatment of cancer
HK1212920A1 (en) Kits and methods for the treatment of cancer using gliadin peptides
PL3016948T3 (en) 2-acylaminothiazoles for the treatment of cancer
EP3104863C0 (en) Salicylates for use in the treatment of cancer
GB201322958D0 (en) Uses of oligouronates in cancer treatment
AU353177S (en) Grinding body
AU352656S (en) Grinding body
GB201313159D0 (en) Finishing Treatment